Drug intelligence / Profile preview

Biovacc-19

Development stage: Unknown
Lead developer: Immunor
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

Biovacc-19 is a preclinical-stage vaccine candidate developed by the Norwegian biotechnology company Immunor for the prevention of COVID-19. Disclosed in 2020, the program involved patent submissions and preclinical studies aimed at addressing the SARS-CoV-2 pandemic. Biovacc-19 is identified as a precursor to the BioVac-19R candidate. The vaccine is designed to elicit a protective immune response against the SARS-CoV-2 virus, although specific details regarding its molecular platform (such as whether it is peptide-based, which is a specialty of the developer) or its precise antigenic targets have not been extensively detailed in public pipeline summaries.

Other names: BioVac-19RBioVac19RBioVac 19R

Targets

S1 (SARS-CoV-2 spike S1 subunit)

Beyond the preview

Go deeper on Biovacc-19.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biovacc-19.

Explore the full profile